APA (7th ed.) Citation

ZH, Z., JQ, L., M, Z., CL, Q., & ZY, X. (2025). Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World journal of gastroenterology, 31(26), 109285. https://doi.org/10.3748/wjg.v31.i26.109285

Chicago Style (17th ed.) Citation

ZH, Zeng, Liu JQ, Zhang M, Qiu CL, and Xu ZY. "Tenofovir Amibufenamide in Chronic Hepatitis B: Lipid Changes and 144-week Safety with Tenofovir Disoproxil Fumarate-to-tenofovir Amibufenamide Switch." World Journal of Gastroenterology 31, no. 26 (2025): 109285. https://doi.org/10.3748/wjg.v31.i26.109285.

MLA (9th ed.) Citation

ZH, Zeng, et al. "Tenofovir Amibufenamide in Chronic Hepatitis B: Lipid Changes and 144-week Safety with Tenofovir Disoproxil Fumarate-to-tenofovir Amibufenamide Switch." World Journal of Gastroenterology, vol. 31, no. 26, 2025, p. 109285, https://doi.org/10.3748/wjg.v31.i26.109285.